We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




License Agreement to Promote Development of Therapeutic CDK Inhibitors

By LabMedica International staff writers
Posted on 29 Jun 2015
Print article
A license agreement has been signed that was designed to promote the development and commercialization of a series of highly-selective cyclin-dependent kinase 7 (CDK7) inhibitors for the treatment of cancer, inflammation, and viral infections.

Cyclin-dependent kinases (CDKs) play a pivotal role in cell cycle control and transcription regulation and have long been considered attractive therapeutic targets. However, selective inhibitors have been difficult to develop, as the CDK active sites are highly conserved. Due to their outstanding specificity for CDK7, CDK inhibitors developed at The Lead Discovery Center (Dortmund, Germany) are thought to be good prospects for overcoming this hurdle. These compounds have demonstrated excellent potency and selectivity in vitro and in vivo.

In order to begin the process of commercializing their CDK inhibitors, The Lead Discovery Center has entered into a license agreement with Qurient Company (Gyeonggi, South Korea).

Under the terms of the agreement The Lead Discovery Center will receive an upfront payment and milestone payments upon the achievement of specific development events. Qurient will fund the future development activities of the collaborative program. The partners plan to progress from the validated lead stage into the clinical development phase. Upon successful proof-of-concept in humans, they will jointly identify a suitable partner for follow-on licensing.

“It is an exciting moment for Qurient to have The Lead Discovery Center as an upstream partner, providing innovative drug discovery programs to our "lead-to-clinical POC" pipelines,” said Dr. Kiyean Nam, CEO of Qurient. “We will join forces to achieve exceptional science and operational excellence until the program reaches mutually beneficial end point.”

“The partnership with Qurient is an essential part of our strategy to create versatile opportunities for accelerating the transfer of our leads into biopharmaceutical development,” said Dr. Bert Klebl, CEO of the Lead Discovery Center. “Qurient combines first-class development expertise with an exceptional commitment to moving innovative projects forward. Together, we can advance our projects swiftly into the clinic and benefit from the dynamic financial environment for biotech companies in South Korea.”

The Lead Discovery Center was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel way to capitalize on the potential of basic research for the discovery of new therapies for diseases with high medical need. Qurient began operations in 2009 as a venture capital funded spin-off Biotechnology company of the Institute Pasteur Korea and is dedicated to bridging gaps between innovative sciences and clinical development for unmet medical needs.

Related Links:

The Lead Discovery Center
Qurient Company


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.